LKT Labs

Biochemicals for Life Science Research

TG100-115

TG100-115

Product ID T2402
Cas No. 677297-51-7
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $146.00 In stock
5 mg $292.00 In stock
10 mg $470.00 In stock
Bulk Quote

Quicklinks

Description

TG100-115 is an inhibitor of p110δ PI3K and p110γ PI3K that exhibits anti-inflammatory and anti-asthma activities. TG100-115 decreases pulmonary eosinophil levels and accumulation of IL-13 and mucin in animal models of asthma and chronic obstructive pulmonary disorder (COPD), decreasing inflammation. TH100-115 also inhibits edema and inflammation induced by VEGF and platelet activating factor (PAF) in other animal models, decreasing development of infarcts and improving cardiac function. As a result of its cardioprotective activity, TG100-115 is currently in clinical trials as a potential treatment to reduce acute myocardial infarctions.

Product Info

Cas No.

677297-51-7
Purity

≥98%
Formula

C18H14N6O2
Formula Wt.

346.34
IUPAC Name

3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
Solubility

DMSO 9 mg/mL (25.98 mM) Water Insoluble Ethanol Insoluble
Appearance

Yellow-Tan Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

T2402 MSDS PDF
Info Sheet

T2402 Info Sheet PDF

References

Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. PMID: 19056934.

Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. PMID: 17371238.

Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. PMID: 17172449.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M1779

    Methyldopa Sesquihydrate

    DOPA decarboxylase inhibitor, indirect α2-adre...

    ≥98%
  • R0253

    Ranitidine Hydrochloride

    Histamine H2 inverse agonist.

    ≥98%
  • V1668

    Vemurafenib

    B-Raf inhibitor.

    ≥98%
  • D1629

    Dehydroepiandrosterone

    Endogenous steroid hormone; ERβ, NMDA, σ1 ago...

    ≥98%
  • B6856

    5-Bromo-2′-Deoxyuridine

    Nucleoside (thymidine) analog.

    ≥98%
  • L1616

    LEE-011

    CDK4/6 inhibitor.

    ≥98%
  • V0146

    Valsartan

    AT1 inhibitor.

    ≥98%
  • B4974

    BMS-777607

    MET and Ron inhibitor.

    ≥99%
  • N5409

    Nocodazole

    Microtubule polymerization inhibitor.

    ≥98%
  • V3345

    Vildagliptin

    DPP4 inhibitor.

    ≥98%
  • P7023

    Pregnenolone

    Endogenous precursor to all steroid hormones; T...

    ≥98%
  • D3228

    Dihydromyristicin

    Found in parsley.

    ≥98%
  • P3348

    Pimecrolimus

    Calcineurin inhibitor, potential TRPV1 agonist....

    ≥99%
  • A4924

    AMG-208

    c-MET and Ron inhibitor.

    ≥98%
  • F1992

    Fexaramine

    FXR agonist.

    ≥98%
  • A5033

    4-Aminosalicylic Acid

    Dihydrofolate reductase inhibitor.

    ≥98%
  • M1977

    Metronidazole

    Nitroimidazole; DNA synthesis inhibitor.

    ≥98%
  • B5871

    Bortezomib

    Proteasome inhibitor.

    ≥98%
  • N3350

    Nimorazole

    Nitroimidazole; hypoxic modifier and radiosensi...

    ≥98%
  • E5221

    Endothelin-2, human

    Endogenous peptide involved in vascular contrac...

    ≥95%